September 2026 Research Update

One study stood out this month for connecting a specific genetic form of complex hereditary spastic paraplegia (SPTSSA-T51I) to a clear chemical pathway in the body, and then testing ways to change that pathway. In a mouse model, the genetic change led to surges of certain fats (sphingolipids) during early life, and the study explored how diet and drug-like approaches altered both the chemistry and neurologic problems. The same report also included a single child with the variant, describing improvement in spasticity after treatment, which is encouraging but still very early evidence. [1]

In the mice, the key finding was that regulation of sphingolipid production was impaired even though the core enzyme activity was preserved, leading to sustained elevation of bioactive sphingolipid intermediates that peaked during postnatal myelination (a period when nerve insulation is developing). When the mice were given dietary serine, sphingolipid buildup increased and neurologic problems became more apparent, including progressive spasticity and signs of nerve and myelin injury. In this model, very early serine exposure also led to severe lung problems and death, emphasizing that changing diet can have major biologic effects in animals with this variant. [1]

The same mouse study tested a way to reduce sphingolipid production using myriocin (an experimental inhibitor of the sphingolipid pathway). Myriocin normalized sphingolipid synthesis and reversed several serine-triggered harms reported in the model, including preventing the lethal outcome seen with early serine exposure. In the human portion, one child with SPTSSA-T51I who received D-cycloserine was reported to have sustained improvement in spasticity, needed less baclofen, and had lower blood levels of NFL (a marker linked to nerve injury). [1]

For families affected by SPTSSA-related complex HSP, this research helps explain a possible "why" behind symptoms by pointing to a specific fat-metabolism pathway that can be measured and changed in a lab model. Right now, the strongest part of the evidence is in mice, and the human information is from a single patient report included within the same study, so it is not yet a proven approach for most people. Still, it adds an important piece to the bigger picture: some HSP subtypes may have treatments that make sense only for that exact genetic cause, and blood markers like NFL may be one way future studies track whether nerve injury is changing. What remains uncertain is how broadly the mouse findings predict human outcomes, and whether these approaches help across different ages and symptom patterns. [1]

This month added two different kinds of progress on measurement in HSP: one study reported a promising lab marker for SPG4 using a simple blood sample, while another warned that some walking stability numbers can shift substantially depending on the calculation choices. Together, these studies highlight both opportunity and caution: different measurements are being explored for HSP research, including possible diagnostic approaches and ways to assess whether future treatments act on their intended target, but technical details can strongly influence results. For patients, this mainly matters as research that could make future studies more comparable and could eventually support earlier or clearer identification in certain subtypes. [2] [3]

In a study of 48 people with genetically confirmed SPG4 and 21 healthy controls, an imaging-based measure in blood immune cells (distance between nucleus and cell centroid, called dcnc) separated SPG4 from controls with high accuracy (AUC 0.98). The marker was reported to be independent of mutation type and disease severity, and it was higher even in asymptomatic carriers, which is important because it suggests the change may show up before noticeable symptoms in some people. The study also reported that dcnc moved in the opposite direction from spastin protein levels, linking the lab readout to a known SPG4-related protein. [2]

A separate analysis focused on how researchers calculate side-to-side walking stability in people with HSP and in healthy adults doing narrow-base walking. The main finding was that how the "base of support" is defined caused larger changes in stability measures than how the "center of mass" is defined, including up to a 35 percentage-point swing in the calculated probability of instability. This matters because it means two studies could report different stability results even if people walked similarly, simply due to different definitions used in analysis. [3]

These studies mainly add research tools rather than immediate changes in care. The SPG4 blood-cell marker is an early signal that a relatively accessible blood sample might help separate SPG4 from people without the condition, and it may be useful in research studies that need a measurable readout beyond symptoms alone. The gait-methods study helps clarify why results from walking labs can be hard to compare, and it supports the idea that standardizing calculation choices could make future HSP mobility research more reliable. What remains uncertain is whether the SPG4 marker changes over time within the same person, and whether either approach will become widely used outside research settings. [2] [3]

Most of this month’s HSP papers were individual or small-family reports that expand the catalog of what different genetic types can look like. Across these reports, a consistent message is that HSP is often more than leg stiffness alone, with some genes linked to learning, thinking, vision, tremor, seizures, dystonia, or nerve problems outside the brain and spinal cord. Two reports also reinforced that certain MRI patterns can be helpful clues toward specific genetic causes, especially SPG11 and SPG15. Because these are small reports, they are best seen as "this can happen" examples rather than typical expectations. [4] [5] [6] [7] [8] [9]

Two reports supported the idea that certain MRI findings can point toward SPG11 or SPG15. In siblings with SPG11, brain MRI showed thinning of the corpus callosum and the "ears of the lynx" sign, described as a potential clue when genetic testing is limited. In a separate SPG15 case with a ZFYVE26 mutation, MRI findings included thinning of the corpus callosum, white matter changes, and the lynx ear sign, alongside nerve testing that showed a marked sensorimotor demyelinating polyneuropathy with signs of anterior horn cell involvement. [9] [5]

Several reports broadened the symptom picture linked to specific genes. A man with SPG7 had significant cognitive impairment across multiple thinking domains; the authors noted emerging reports of thinking problems in SPG7 and said some of the specific deficits they found had not been described before, which may prompt more attention to cognition in some SPG7 presentations. In a family with an adult-onset TUBB4A variant, the reported picture included spasticity with tremor and mild executive difficulties, with advanced imaging suggesting gray matter and white matter changes even when routine MRI findings were limited. [4] [6]

Early-life presentations were highlighted in an infant with a CYP2U1 variant linked to SPG56, where seizures and prominent dystonia were the main early issues and no leg spasticity was seen over 6 months of follow-up. The report noted improvement of seizures and dystonia while on sodium valproate and levetiracetam, and MRI showed delayed myelination. A separate SPG11 case in an 18-year-old described a homozygous frameshift variant with progressive lower-limb stiffness and walking difficulty over 2 years, adding another example to the range of SPG11 presentations. [7] [10]

One small family report suggested a possible link between a PAX6 variant and a combination of congenital cataracts with mild spastic paraplegia. The study found that PAX6 RNA levels in blood were unchanged, but the variant increased transcriptional activity in a laboratory assay, leaving the biologic connection to spastic paraplegia plausible but not yet clear. For families with prominent eye findings plus mild spasticity, this report adds to the list of genes that might be considered in research discussions, but replication is needed. [8]

For patients and caregivers, these reports mainly add clarity about what HSP can include, especially in specific genetic subtypes, rather than changing treatment today. They help explain why two people with "HSP" can look very different, and they reinforce that brain imaging and nerve testing sometimes provide clues that guide genetic answers. The uncertainty is that single cases and small families cannot tell how common any feature is, such as cognitive changes in SPG7 or dystonia-first presentation in SPG56. Even so, these reports can be useful in conversations about testing and in setting expectations that symptoms beyond walking can be part of some HSP types. [4] [7] [9]

One laboratory study this month focused on Atlastin, an HSP-linked gene, to understand what goes wrong inside nerve cells. The main message was that the cell structure being studied (a network inside cells called the endoplasmic reticulum, or ER) did not simply fall apart in mutants, but showed a more specific problem at synapses as development progressed. This shifts the focus from a purely structural defect to a functional defect in the ER in this model. [11]

In Drosophila (fruit fly) motor neurons with Atlastin mutations, imaging showed the ER still formed robust networks with only mild changes in structure and movement. The striking result was that a marker that should stay inside the ER gradually appeared in the surrounding cell fluid specifically at synapses during larval development, while remaining correctly localized in cell bodies, axons, and muscles. This pattern suggests the problem may be tied to how synapses handle ER contents over time, rather than a global ER collapse. [11]

This is early, animal-based research and it does not predict near-term changes in diagnosis or treatment. Its value for patients is in narrowing down what might be going wrong in nerve cells in at least one HSP-related gene, which can guide future therapy ideas and laboratory tests. What remains uncertain is whether the same synapse-specific ER problem happens in people with Atlastin-related HSP, and whether it is a driver of symptoms or one of several downstream changes. For now, it mainly adds to the long-term effort to connect gene changes to specific cell problems that could someday be targeted. [11]

One paper this month addressed a practical life issue for many families: moving from child-focused neurology care to adult care in rare neurologic diseases, including hereditary spastic paraplegias. The study brought together international experts and reached agreement on a set of shared recommendations meant to apply across several rare conditions. This kind of work does not measure symptom change, but it can help make transitions less variable from one clinic or country to another. [12]

Using a scoping review and a Delphi consensus process, 47 specialists from 12 countries evaluated 59 statements about transitional care across five rare neurologic disease groups, including HSP. The outcome was 17 recommendations that reached consensus across all groups. The report does not provide results on patient outcomes, since it focused on expert agreement rather than testing an intervention. [12]

For patients and caregivers, this work matters most at the planning level rather than the medical-treatment level. It signals growing international agreement on what should be included when young people with HSP move into adult services, which may support more consistent care experiences over time. Because this was an expert consensus project, it cannot tell whether following the recommendations improves health, independence, or quality of life, and those results would require future studies. Still, it helps clarify that transition planning is being treated as a shared need across rare neurologic diseases, not something families have to navigate alone without guidance. [12]